Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia

doi:10.12998/wjcc.v10.i4.1217

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3837)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

270

WORD

166

HTML

1989

Tables (1-6)

327

Sum=2752

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

316

Download

769

Sum=1085

Feb 6, 2022 (publication date) through Feb 9, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Feb 6, 2022; 10(4): 1217-1225
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1217

Table 1 General data comparison between patient groups

Group	Control group (n = 60)	Observation group (n = 60)
Male/female	35/25	33/27
Age (yr)	60.14 ± 8.23	59.96 ± 8.17
Dialysis time (mo)	12.86 ± 2.11	12.78 ± 2.53
Dialysis frequency (sub/w)	2.81 ± 0.56	2.78 ± 0.61
Dialysis duration (h/w)	10.52 ± 2.12	10.48 ± 2.25
Cause of renal failure (glomerulonephritis/hypertension/diabetes/others)	24/16/14/6	25/13/15/7
Education background (Junior and below/High and Junior/undergraduate and above)	12/35/13	10/34/16
Marriage status (Unwed/married/divorced)	6/47/7	9/46/5
Fee payment method (Medical care/Rural cooperative care/self-funded)	43/13/4	38/17/5

Table 2 Comparison of blood parathyroid hormone, calcium, phosphorus, and calcium-phosphorus product levels between the two groups (mean ± SD)

Group	Number of examples	Time	Blood, iPTH (pg/mL)	Blood-based Ca (mmol/L)	Blood-P (mmol/L)	Ca × P (mmol²/L²)
Control group	60	Before the intervention	379.63 ± 43.25	2.30 ± 0.25	2.15 ± 0.36	4.82 ± 0.69
		Intervention for 3 mo	312.36 ± 36.21^a	2.19 ± 0.22^a	2.02 ± 0.29^a	4.61 ± 0.56^a
		Intervention for 6 mo	295.69 ± 21.44^a	2.11 ± 0.26^a	2.05 ± 0.25^a	4.55 ± 0.56^a
Observation group	60	Before the intervention	383.45 ± 42.96	2.28 ± 0.26	2.19 ± 0.33	1.78 ± 0.78
		Intervention for 3 mo	296.88 ± 28.02^a^,^d	2.11 ± 0.21^a^,^d	1.73 ± 0.31^a^,^d	4.15 ± 0.46 ^a^,^d
		Intervention for 6 mo	249.63 ± 23.44^a^,^d	2.08 ± 0.26^a^,^d	1.70 ± 0.26^a^,^d	4.08 ± 0.49^a^,^d

^aP < 0.05 vs those before intervention in this group.

^dP < 0.05 vs the control group.

iPTH: Serum parathyroid hormone; Ca: Calcium; P: Phosphorus; Ca × P calcium-phosphorus product.

Table 3 Comparison of renal function indicators between the two groups (mean ± SD)

Group	Number of examples	Time	Scr (μmol/L)	BUN (mmol/L)
Control group	60	Before the intervention	1120.36 ± 241.36	36.85 ± 10.52
		Intervention for 3 mo	1055.89 ± 269.33^a	35.84 ± 9.88^a
		Intervention for 6 mo	1078.96 ± 271.54^a	37.11 ± 12.45^a
Observation group	60	Before the intervention	1098.36 ± 268.11	37.32 ± 9.25
		Intervention for 3 mo	1102.42 ± 301.02^a^,^d	40.02 ± 10.47^a^,^d
		Intervention for 6 mo	1083.67 ± 274.25^a^,^d	38.96 ± 9.02^a^,^d

^aP < 0.05 vs those before intervention in this group.

^dP < 0.05 vs the control group.

Scr: Serum creatinine; BUN: Blood urea nitrogen.

Table 4 Comparison of patient satisfaction between the two groups, n (%)

Group	Number of examples	Time	Very satisfied	Satisfaction	Not satisfied	Satisfaction level
Control group	60	Three months	28 (46.67)	20 (33.33)	12 (20.00)	48 (80.00)
Control group	60	Six months	34 (56.67)	22 (36.67)	4 (6.67)	56 (93.33)
Observation group	60	Three months	22 (36.67)	21 (35.00)	17 (28.33)	43 (71.67)^a
Observation group	60	Six months	30 (50.00)	24 (40.00)	6 (10.00)	54 (90.00)^a

^aP < 0.05 vs the control group.

Table 5 Comparison of EQ-5D-3L scores between the two groups (mean ± SD, points)

Group	Number of examples	Time	Action ability	Self-care	Daily activities	Pain and discomfort	Anxiety and frustration	VAS score
Control group	60	Before the intervention	2.03 ± 0.44	2.12 ± 0.51	1.78 ± 0.62	2.16 ± 0.41	2.03 ± 0.52	58.25 ± 12.03
		Intervention for 3 mo	1.54 ± 0.32^a	1.43 ± 0.43^a	1.21 ± 0.32^a	1.46 ± 0.37^a	1.50 ± 0.46^a	69.36 ± 7.14^a
		Intervention for 6 mo	1.56 ± 0.41^a	1.42 ± 0.32^a	1.26 ± 0.25^a	1.38 ± 0.26^a	1.44 ± 0.51^a	68.23 ± 8.27^a
Observation group	60	Before the intervention	2.01 ± 0.42	2.14 ± 0.47	1.75 ± 0.56	2.12 ± 0.43	2.06 ± 0.47	57.44 ± 12.85
		Intervention for 3 mo	1.32 ± 0.25^a^,^d	1.26 ± 0.37^a^,^d	1.09 ± 0.26^a^,^d	1.24 ± 0.33^a^,^d	1.34 ± 0.39^a^,^d	75.89 ± 6.98^a^,^d
		Intervention for 6 mo	1.33 ± 0.21^a^,^d	1.22 ± 0.32^a^,^d	1.05 ± 0.24^a^,^d	1.25 ± 0.29^a^,^d	1.29 ± 0.27^a^,^d	77.02 ± 8.45^a^,^d

^aP < 0.05 vs those before intervention in this group.

^dP < 0.05 vs the control group.

VAS: Visual analogue scale.

Table 6 Comparison of disease-related knowledge and compliance scores between the two groups (mean ± SD, points)

Group	Number of examples	Time	Disease knowledge	Diet knowledge	Drug-taking knowledge	Compliance
Control group	60	Before the intervention	52.14 ± 6.14	61.14 ± 5.85	46.96 ± 5.25	58.23 ± 10.02
		Intervention for 3 mo	68.96 ± 5.44^a	73.36 ± 6.02^a	68.11 ± 6.36^a	74.01 ± 6.59^a
		Intervention for 6 mo	69.23 ± 6.01^a	71.45 ± 5.22^a	64.25 ± 5.23^a	72.85 ± 6.98^a
Observation group	60	Before the intervention	51.92 ± 8.98	60.88 ± 7.23	48.02 ± 6.32	57.96 ± 8.97
		Intervention for 3 mo	87.12 ± 6.55^a^,^d	84.96 ± 8.02^a^,^d	82.55 ± 7.65^a^,^d	87.55 ± 7.14^a^,^d
		Intervention for 6 mo	86.25 ± 7.12^a^,^d	84.98 ± 7.96^a^,^d	85.02 ± 6.44 ^a^,^d	86.96 ± 8.05^a^,^d

^aP < 0.05 vs those before intervention in this group.

^dP < 0.05 vs the control group.

Citation: Feng XD, Xie X, He R, Li F, Tang GZ. Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia. World J Clin Cases 2022; 10(4): 1217-1225
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1217.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1217